Artelo Biosciences (ARTL)
(Delayed Data from NSDQ)
$1.06 USD
-0.07 (-5.89%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.15 +0.09 (8.49%) 5:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Income Statements
Fiscal Year end for Artelo Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 10 | 10 | 7 | 7 | 5 |
Income After Depreciation & Amortization | -10 | -10 | -7 | -7 | -5 |
Non-Operating Income | 1 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -9 | -10 | -7 | -7 | -5 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -9 | -10 | -7 | -7 | -5 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -9 | -10 | -7 | -7 | -5 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -10 | -10 | -7 | -7 | -5 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -10 | -10 | -7 | -7 | -5 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.96 | 2.83 | 1.25 | 0.25 | 0.15 |
Diluted EPS Before Non-Recurring Items | -3.14 | -3.56 | -6.00 | -18.74 | -21.89 |
Diluted Net EPS (GAAP) | -3.14 | -3.56 | -6.00 | -6.00 | -18.89 |
Fiscal Year end for Artelo Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 2.52 | 2.59 | 3.24 | 2.62 | 1.78 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.52 | -2.59 | -3.24 | -2.62 | -1.78 |
Non-Operating Income | 0.08 | 0.11 | 0.17 | 0.17 | 0.19 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -2.43 | -2.48 | -3.07 | -2.45 | -1.60 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.43 | -2.48 | -3.07 | -2.45 | -1.60 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.43 | -2.48 | -3.07 | -2.45 | -1.60 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 3.23 | 3.21 | 3.12 | 2.95 | 2.86 |
Diluted EPS Before Non-Recurring Items | -0.75 | -0.78 | -0.99 | -0.83 | -0.56 |
Diluted Net EPS (GAAP) | -0.75 | -0.78 | -0.99 | -0.83 | -0.56 |